Aravive Past Earnings Performance

Past criteria checks 0/6

Aravive's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been declining at an average rate of 6.2% per year.

Key information

-12.3%

Earnings growth rate

29.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-6.2%
Return on equity-2,342.6%
Net Margin-569.7%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Revenue & Expenses Breakdown

How Aravive makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ARAV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 237-40130
30 Jun 239-77130
31 Mar 2310-113130
31 Dec 229-76130
30 Sep 229-60120
30 Jun 226-56120
31 Mar 228-44110
31 Dec 217-39110
30 Sep 2112-30110
30 Jun 2110-30110
31 Mar 216-28110
31 Dec 206-31130
30 Sep 200-31130
30 Jun 200-26130
31 Mar 203-24130
31 Dec 195-18140
30 Sep 196-65210
30 Jun 196-65230
31 Mar 193-72250
31 Dec 181-76260
30 Sep 1840623-93
30 Jun 1840-3725-51
31 Mar 1840-6426-22
31 Dec 1740-85290
30 Sep 170-13828110
30 Jun 170-1162888
31 Mar 170-1012676
31 Dec 160-962472
30 Sep 160-942171
30 Jun 160-872266
31 Mar 160-842161
31 Dec 150-822060
30 Sep 150-782256
30 Jun 150-711851
31 Mar 150-601645
31 Dec 140-831433
30 Sep 140-731224
30 Jun 140-64919
31 Mar 140-59616
31 Dec 130-18415

Quality Earnings: ARAV is currently unprofitable.

Growing Profit Margin: ARAV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARAV is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare ARAV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARAV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: ARAV has a negative Return on Equity (-2342.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/29 07:24
End of Day Share Price 2024/01/29 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aravive, Inc. is covered by 16 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBTIG
John NewmanCanaccord Genuity
Louise ChenCantor Fitzgerald & Co.